AI Labs
Tempus AI
A precision medicine company applying AI to genomic sequencing and clinical data, combining diagnostics and data-licensing businesses to accelerate oncology treatment decisions and drug development. Tempus AI reported Q1 2026 revenue of $348.1 million (up 36.1% year-over-year), with Diagnostics revenue of $261.1 million (driven by 28% oncology volume growth); minimal residual disease test volume reached approximately 6,500 tests in Q1 2026, up roughly 500% year-over-year.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources · 1 government/SEC filing · 84% avg. source confidence
- U.S. Securities and Exchange Commission (EDGAR) — Tempus AI FY2025 Annual Report (Form 10-K), filed with the SEC95% source confidence
- Tempus AI Q1 2026 earnings release — Tempus AI Q1 2026 revenue up 36% to $348M, raises full-year guidance to $1.6B82% source confidence
- Tempus AI Q1 2026 earnings coverage (Tickeron) — Tempus AI's MRD cancer-monitoring test volume surges roughly 500% year-over-year in Q1 202674% source confidence
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Jul 28, 2026
Dependency Map
What Tempus AI depends on below, and who depends on Tempus AI above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.